Aims, Settings, and Design: The COVID-19 pandemic has forced upon sudden lifestyle changes because of nationwide lockdowns mandating isolation at home, affecting daily habits and lifestyle changes. The present study was conducted with an aim to assess these changes brought about because of COVID-19 lockdown restrictions. Methods: The web-survey aimed to understand the immediate impact of the COVID-19 lockdown on people by using a structured questionnaire collecting demographic, lifestyle, and dietary information. The survey was disseminated online among the literate, urban, adult population with internet access. Results: Of the 1,200 people who received the survey, a total of 1,008 respondents participated in the study, aged between 18 and 81 years (Median- 24). An increase in daily screen time has been observed in 56.7% of the population. A decrease in work-related stress was observed in 43% of the population, sleep pattern improved in 36.7% people, and 27.1% of the inactive population showed increased physical activity. A significant decrease in the proportion of people consuming junk food (73.8%), alcohol (27.6%), and smoking (8.1%) was observed. Conclusions: The present web-based survey study suggests a significant change in the lifestyle and dietary patterns of people brought about because of the COVID-19 lockdown most highly seen as a major increase in screen usage and a decrease in junk food consumption.
Context: Following rapid spread of COVID-19, WHO on March 11, 2020, declared COVID-19 a global pandemic. Diabetes is known to confer increased risk for various infections. Studies from outside India have shown more aggressive course of COVID 19 Pneumonia in diabetic patients. Material and methods:Aretrospective observational study was carried out at Mahatma Gandhi Medical College and Hospital, Jaipur. Data from electronic medical records of seven thirty-one patient admitted from 15 October 2020 to 30 November 2020 were reviewed and analysed Results: Patients with diabetes had signicantly higher need of oxygen therapy and ICU admission. No difference was observed in mortality rates in the two group of patients.Conclusion: Diabetes patients appear to be at higher risk of severe illness from COVID-19 than those without diabetes.
A bstract Purpose End-organ damage in coronavirus disease-2019 (COVID-19) is linked to “cytokine storm” and excessive release of inflammatory mediators. Various novel therapies have been used in COVID-19 including urinary trypsin inhibitor therapy. This study explores the efficacy of ulinastatin in COVID-19. Materials and methods We retrieved the medical records of patients admitted during one month and did a propensity score analysis to create matched treatment and control groups. We analyzed these groups and the outcomes were presented with appropriate statistics. Survival curve was prepared to compare the survival effect of ulinastatin therapy at the end of hospitalization, among both the groups. Results A total of 736 patients were admitted, and after adjusting the data with propensity score matching, 55 cases were selected by the system. On the final outcome analysis, we found that intensive care unit (ICU) length of stay [median (interquartile range) days 3 (3.5–7.8) vs 2 (0-4); p -value 0.28] in control vs intervention groups, and in hospital mortality (odds ratio: 0.491, CI 95%: 0.099–2.44, p -value 0.435) were not statistically different among the groups. In survival plot analysis also, there was no statistical difference ( p -value 0.414) among both the groups. Conclusion: In this retrospective study, we conclude that the final outcome of the ICU length of stay, and overall, in hospital mortality were not different among both the groups. Hence, adequately powered randomized control trials are urgently required to confirm any benefit of ulinastatin therapy in COVID-19 treatment. How to cite this article Jain A, Kasliwal R, Jain SS, Jain R, Gupta D, Gupta P, et al. Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19. Indian J Crit Care Med 2022;26(6):696–703.
Aims and Objectives: This study aims to assess the effects of COVISHIELD vaccine on humans after first dose of vaccination. In this study we have evaluated vaccine’s effect after first dose on health officials in central India.
Posterior reversible encephalopathy syndrome (PRES) is increasingly being recognised as a clinic-neuro-radiological complication of eclampsia, with the availability of better imaging techniques. Preeclampsia and eclampsia continues to be one of the leading cause of both maternal and foetal morbidity and mortality worldwide. PRES is a diagnostic and therapeutic challenge when it develops in a case of preeclampsia. Reported here a case of 21 years old primi gravida, presenting in emergency OPD with 30 weeks pregnancy, history of seizures and in unconscious state. She was diagnosed to have PRES by imaging. PRES is associated with various clinical conditions i.e. hypertensive encephalopathy, renal failure, auto immune disorders and treatment with cytotoxic medication and presence with headache, encephalopathy, seizures, cortical visual disturbances or blindness. Early recognition of the condition with prompt management can prevent permanent neurological damage antihypertensive, control of seizures and anti-oedema measures are the main stay of the treatment as prompt control of BP will cause reversal of the syndrome. Clinical improvement with prompt resolution of the neurological deficit in the reported case highlights the importance of early suspicion, diagnosis and management of PRES in order to prevent short and long term neurological damage.
Nucleoside analogue reverse transcriptase inhibitors (NRTI) have been used to treat HIV-infected patients for more than 20 years, and although their range of toxicity is considered mild, some cases of severe and even fatal toxicity have been described mainly attributed to mitochondrial dysfunction. We report a unique case of stavudine induced hepatic steatosis, hyperlactatemia, lipodystrophy, peripheral neuropathy, dyslipidemia and hyperglycemia in a patient along with zidovudine induced anemia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.